Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 2/2024

02-02-2024 | Antibiotic | Review

Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections

Authors: Majid Taati Moghadam, Ali Mojtahedi, Shakiba Salamy, Razieh Shahbazi, Naghmeh Satarzadeh, Majid Delavar, Mohammad Taghi Ashoobi

Published in: Infection | Issue 2/2024

Login to get access

Abstract

Purpose

Over the last decade, surgery rates have risen alarmingly, and surgical-site infections are expanding these concerns. In spite of advances in infection control practices, surgical infections continue to be a significant cause of death, prolonged hospitalization, and morbidity. As well as the presence of bacterial infections and their antibiotic resistance, biofilm formation is one of the challenges in the treatment of surgical wounds.

Methods

This review article was based on published studies on inpatients and laboratory animals receiving phage therapy for surgical wounds, phage therapy for tissue and bone infections treated with surgery to prevent recurrence, antibiotic-resistant wound infections treated with phage therapy, and biofilm-involved surgical wounds treated with phage therapy which were searched without date restrictions.

Results

It has been shown in this review article that phage therapy can be used to treat surgical-site infections in patients and animals, eliminate biofilms at the surgical site, prevent infection recurrence in wounds that have been operated on, and eradicate antibiotic-resistant infections in surgical wounds, including multi-drug resistance (MDR), extensively drug resistance (XDR), and pan-drug resistance (PDR). A cocktail of phages and antibiotics can also reduce surgical-site infections more effectively than phages alone.

Conclusion

In light of these encouraging results, clinical trials and research with phages will continue in the near future to treat surgical-site infections, biofilm removal, and antibiotic-resistant wounds, all of which could be used to prescribe phages as an alternative to antibiotics.
Literature
1.
Chopra H, Islam MA, Sharun K, Emran TB, Al-Tawfiq JA, Dhama K. Recent advances in the treatment of biofilms induced surgical site infections. Int J Surg. 2023;109:65–7.PubMedPubMedCentralCrossRef
2.
Hrynyshyn A, Simões M, Borges A. Biofilms in surgical site infections: recent advances and novel prevention and eradication strategies. Antibiotics. 2022;11:69.PubMedPubMedCentralCrossRef
3.
Mora-Guzman I, Rubio-Perez I, González RM, Garcia DD, Martin-Perez E. Surgical Site Infection by Carbapenemase-producing Enterobacteriaceae: a challenge for today’s surgeons. Cirugía Española (English Edition). 2020;98:342–9.CrossRef
4.
Menz BD, Charani E, Gordon DL, Leather AJ, Moonesinghe SR, Phillips CJ. Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infection and Drug Resistance. 2021:5235–52.
5.
Cesta N, Pini M, Mulas T, Materazzi A, Ippolito E, Wagemans J, et al., editors. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitro analysis. Open Forum Infectious Diseases; 2023: Oxford University Press US.
6.
Santamaría-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, García-Quintanilla M. Bacteriophage-antibiotic combination therapy against pseudomonas aeruginosa. Antibiotics. 2023;12:1089.PubMedPubMedCentralCrossRef
7.
Metsemakers W-J, Onsea J, Moriarty TF, Pruidze N, Nadareishvili L, Dadiani M, Kutateladze M. Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Clin Microbiol Infect. 2023.
8.
Taati Moghadam M, Amirmozafari N, Shariati A, Hallajzadeh M, Mirkalantari S, Khoshbayan A, Masjedian Jazi F. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resistance. 2020:45–61.
9.
Mousavi SM, Babakhani S, Moradi L, Karami S, Shahbandeh M, Mirshekar M, et al. Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria. Curr Microbiol. 2021:1–14.
10.
Moghadam MT, Chegini Z, Norouzi A, Dousari AS, Shariati A. Three-decade failure to the eradication of refractory Helicobacter pylori infection and recent efforts to eradicate the infection. Curr Pharm Biotechnol. 2021;22:945–59.PubMedCrossRef
11.
12.
13.
McDermott KW, Freeman WJ, Elixhauser A. Overview of operating room procedures during inpatient stays in US hospitals, 2014: statistical brief# 233. 2018.
14.
15.
Kolasiński W. Surgical site infections–review of current knowledge, methods of prevention. Polish J Surg. 2019;91:41–7.
16.
Krezalek MA, Hyoju S, Zaborin A, Okafor E, Chandrasekar L, Bindokas V, et al. Can methicillin-resistant Staphylococcus aureus silently travel from the gut to the wound and cause postoperative infection? Modeling the “Trojan Horse Hypothesis.” Ann Surg. 2018;267:749–58.PubMedCrossRef
17.
Garvin KL, Miller RE, Gilbert TM, White AM, Lyden ER. Late reinfection may recur more than 5 years after reimplantation of THA and TKA: analysis of pathogen factors. Clin Orthop Relat Res. 2018;476:345.PubMedPubMedCentralCrossRef
18.
Nobuhara H, Yanamoto S, Funahara M, Matsugu Y, Hayashida S, Soutome S, et al. Effect of perioperative oral management on the prevention of surgical site infection after colorectal cancer surgery: A multicenter retrospective analysis of 698 patients via analysis of covariance using propensity score. Medicine. 2018;97(40).
19.
Robson MC. Wound infection: a failure of wound healing caused by an imbalance of bacteria. Surg Clin North Am. 1997;77:637–50.PubMedCrossRef
20.
Cochran AR, Ong KL, Lau E, Mont MA, Malkani AL. Risk of reinfection after treatment of infected total knee arthroplasty. J Arthroplasty. 2016;31:156–61.PubMedCrossRef
21.
Sartelli M, C. Hardcastle T, Catena F, Chichom-Mefire A, Coccolini F, Dhingra S, et al. Antibiotic use in low and middle-income countries and the challenges of antimicrobial resistance in surgery. Antibiotics. 2020;9(8):497.
22.
Hope D, Ampaire L, Oyet C, Muwanguzi E, Twizerimana H, Apecu RO. Antimicrobial resistance in pathogenic aerobic bacteria causing surgical site infections in Mbarara regional referral hospital. Southwestern Uganda Sci Rep. 2019;9:1–10.
23.
Adrien HM, Alexandre AS, Romaric TS, Fanny H-a, Holden FO, Bio TS, et al. Risk factors of surgical site infection at the regional and teaching hospital center of borgou (BENIN). Int J Clin Biomed Res. 2017:1–4.
24.
Iskandar K, Sartelli M, Tabbal M, Ansaloni L, Baiocchi GL, Catena F, et al. Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resistant bacteria. World J Emergency Surg. 2019;14:1–14.CrossRef
25.
Labricciosa FM, Sartelli M, Correia S, Abbo LM, Severo M, Ansaloni L, et al. Emergency surgeons’ perceptions and attitudes towards antibiotic prescribing and resistance: a worldwide cross-sectional survey. World J Emergency Surg. 2018;13:1–9.CrossRef
26.
27.
Fanny MA, Holden FO, Bio T-S, Robert A, Felix AS, Yves DA, Delphin MK. Epidemiological aspects of surgical site infections in an income country: the case of regional hospital centre, Borgou (Benin). Health Sci. 2017;6:29–33.
28.
Foschi D, Yakushkina Ao, Cammarata F, Lamperti G, Colombo F, Rimoldi S, et al. Surgical site infections caused by multi-drug resistant organisms: a case–control study in general surgery. Updates Surg. 2022;74(5):1763–71.
29.
Badia JM, Casey AL, Rubio-Pérez I, Crosby C, Arroyo-García N, Balibrea JM. A survey to identify the breach between evidence and practice in the prevention of surgical infection: Time to take action. Int J Surg. 2018;54:290–7.PubMedCrossRef
30.
Sartelli M, Kluger Y, Ansaloni L, Coccolini F, Baiocchi GL, Hardcastle TC, et al. Knowledge, awareness, and attitude towards infection prevention and management among surgeons: identifying the surgeon champion. World J Emergency Surg. 2018;13:1–6.CrossRef
31.
32.
Moghadam MT, Chegini Z, Khoshbayan A, Farahani I, Shariati A. Helicobacter pylori biofilm and new strategies to combat it. Curr Mol Med. 2021;21:549–61.PubMed
33.
Wolcott R, Cutting KF, Dowd S. Surgical site infections: biofilms, dehiscence and delayed healing. Wounds UK. 2008;4:108–13.
34.
35.
Edmiston CE, McBain A, Kiernan M, Leaper D. A narrative review of microbial biofilm in postoperative surgical site infections: clinical presentation and treatment. J Wound Care. 2016;25:693–702.PubMedCrossRef
36.
Dhar Y, Han Y. Current developments in biofilm treatments: wound and implant infections. Eng Regeneration. 2020;1:64–75.CrossRef
37.
Darvishi S, Tavakoli S, Kharaziha M, Girault HH, Kaminski CF, Mela I. Advances in the sensing and treatment of wound biofilms. Angew Chem Int Ed. 2022;61: e202112218.CrossRef
38.
Wu H, Moser C, Wang H-Z, Høiby N, Song Z-J. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1–7.PubMedCrossRef
39.
Miller KE, Hontanilla B, Cabello A, Marre D, Armendariz L, Leiva J. The effect of late infection and antibiotic treatment on capsular contracture in silicone breast implants: a rat model. J Plast Reconstr Aesthet Surg. 2016;69:70–6.PubMedCrossRef
40.
Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017;15:740–55.PubMedPubMedCentralCrossRef
41.
Ribeiro JR. Opportunities and regulatory challenges of phage therapy 2023.
42.
Kaur R, Sethi N. Phage therapy as an alternative treatment in the fight against AMR: Real-world problems and possible futures. Emerging modalities in mitigation of antimicrobial resistance: Springer; 2022. 357–74.
43.
Jeschke P, Starikov EB. Agricultural Biocatalysis: Biological and Chemical Applications: CRC Press; 2022.
44.
Wallenborn JT, Vonaesch P. Intestinal microbiota research from a global perspective. Gastroenterol Report. 2022; 10:goac010.
45.
Jamil T, Mehmood A, Farhan M, Kalim F, Hadi F, Younas K, et al. Bacteriophage therapy: effective antibiotic replacer against emerging ghost of antimicrobial resistant bacteria. One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan. 2023;1:158–67.
46.
47.
Sharma N, Chhillar AK, Dahiya S, Punia A, Choudhary P, Gulia P, et al. Chemotherapeutic Strategies for Combating Staphylococcus aureus Infections. Mini Rev Med Chem. 2022;22(1):26–42.PubMedCrossRef
48.
Khalid A, Lin RC, Iredell JR. A phage therapy guide for clinicians and basic scientists: background and highlighting applications for developing countries. Front Microbiol. 2021;11: 599906.PubMedPubMedCentralCrossRef
49.
Royer S, Morais AP, da Fonseca Batistão DW. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Arch Microbiol. 2021;203:1271–9.PubMedCrossRef
50.
Caflisch KM, Suh GA, Patel R. Biological challenges of phage therapy and proposed solutions: a literature review. Expert Rev Anti Infect Ther. 2019;17:1011–41.PubMedPubMedCentralCrossRef
51.
Liang S, Qi Y, Yu H, Sun W, Raza SHA, Alkhorayef N, et al. bacteriophage therapy as an application for bacterial infection in China. Antibiotics. 2023;12:417.PubMedPubMedCentralCrossRef
52.
Letarov A, Kulikov E. Adsorption of bacteriophages on bacterial cells. Biochem Mosc. 2017;82:1632–58.CrossRef
53.
Dion MB, Oechslin F, Moineau S. Phage diversity, genomics and phylogeny. Nat Rev Microbiol. 2020;18:125–38.PubMedCrossRef
54.
Ackermann H-W. Phage classification and characterization. Bacteriophages: Methods and protocols, volume 1: Isolation, characterization, and interactions. 2009:127–40.
55.
Tolstoy I, Kropinski AM, Brister JR. Bacteriophage taxonomy: an evolving discipline. Bacteriophage Therapy: From Lab to Clinical Practice. 2018:57–71.
56.
57.
Hitchcock NM, Devequi Gomes Nunes D, Shiach J, Valeria Saraiva Hodel K, Dantas Viana Barbosa J, Alencar Pereira Rodrigues L, et al. Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Viruses. 2023;15:1020.
58.
59.
60.
Mavrich TN, Hatfull GF. Bacteriophage evolution differs by host, lifestyle and genome. Nat Microbiol. 2017;2:1–9.CrossRef
61.
Dunstan RA, Bamert RS, Belousoff MJ, Short FL, Barlow CK, Pickard DJ, et al. Mechanistic insights into the capsule-targeting depolymerase from a Klebsiella pneumoniae bacteriophage. Microbiol Spectrum. 2021;9:e01023-e1121.CrossRef
62.
63.
Dunne M, Hupfeld M, Klumpp J, Loessner MJ. Molecular basis of bacterial host interactions by Gram-positive targeting bacteriophages. Viruses. 2018;10:397.PubMedPubMedCentralCrossRef
64.
Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25:219–32.PubMedCrossRef
65.
Pfeifer E, Bonnin RA, Rocha EP. Phage-Plasmids spread antibiotic resistance genes through infection and lysogenic conversion. MBio. 2022;13:e01851-e1922.PubMedPubMedCentralCrossRef
66.
Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:513.PubMedPubMedCentralCrossRef
67.
Lerminiaux NA, Cameron AD. Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol. 2019;65:34–44.PubMedCrossRef
68.
Riedel S, Hobden J, Miller S, Morse S, Mietzner T, Detrick B, et al. Microbial Genetics. Jawetz, Melnick, & Adelberg’s Medical Microbiology; McGraw Hill: New York, NY, USA. 2019.
69.
70.
71.
Boeckaerts D, Stock M, De Baets B, Briers Y. Identification of phage receptor-binding protein sequences with hidden markov models and an extreme gradient boosting classifier. Viruses. 2022;14:1329.PubMedPubMedCentralCrossRef
72.
Boeckaerts D, Stock M, Criel B, Gerstmans H, De Baets B, Briers Y. Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins. Sci Rep. 2021;11:1467.PubMedPubMedCentralCrossRef
73.
Floccari VA, Dragoš A. Host control by SPβ phage regulatory switch as potential manipulation strategy. Curr Opin Microbiol. 2023;71: 102260.PubMedCrossRef
74.
White K, Yu J-H, Eraclio G, Dal Bello F, Nauta A, Mahony J, van Sinderen D. Bacteriophage-host interactions as a platform to establish the role of phages in modulating the microbial composition of fermented foods. Microbiome Res Reports. 2022:1–19.
75.
de Jonge PA, Nobrega FL, Brouns SJ, Dutilh BE. Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 2019;27:51–63.PubMedCrossRef
76.
Melo LD, Oliveira H, Pires DP, Dabrowska K, Azeredo J. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 2020;46:78–99.PubMedCrossRef
77.
El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis. 2019;69:167–78.PubMedCrossRef
78.
Nadareishvili L, Hoyle N, Nakaidze N, Nizharadze D, Kutateladze M, Balarjishvili N, et al. Bacteriophage therapy as a potential management option for surgical wound infections. Phage. 2020;1:158–65.PubMedPubMedCentralCrossRef
79.
Hassannia M, Naderifar M, Salamy S, Akbarizadeh MR, Mohebi S, Moghadam MT. Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications. Bioprocess and Biosystems Engineering. 2023:1–12.
80.
Boroujeni MB, Mohebi S, Malekian A, Shahraeini SS, Gharagheizi Z, Shahkolahi S, et al. The therapeutic effect of engineered phage, derived protein and enzymes against superbug bacteria. Biotechnology and Bioengineering. 2023.
81.
Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother. 2016;60:5806–16.PubMedPubMedCentralCrossRef
82.
Morris JL, Letson HL, Elliott L, Grant AL, Wilkinson M, Hazratwala K, McEwen P. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus. PLoS ONE. 2019;14: e0226574.PubMedPubMedCentralCrossRef
83.
Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21:427–36.PubMedCrossRef
84.
Rubalskii E, Ruemke S, Salmoukas C, Boyle EC, Warnecke G, Tudorache I, et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics. 2020;9:232.PubMedPubMedCentralCrossRef
85.
Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage therapy of chronic nonhealing wound: clinical study. Int J Low Extrem Wounds. 2019;18:171–5.PubMedCrossRef
86.
Rostkowska OM, Międzybrodzki R, Miszewska‐Szyszkowska D, Górski A, Durlik M. Treatment of recurrent urinary tract infections in a 60‐year‐old kidney transplant recipient. The use of phage therapy. Transpl Infect Dis. 2021;23:e13391.
87.
Tkhilaishvili T, Winkler T, Müller M, Perka C, Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64:e00924-e1019.PubMedPubMedCentralCrossRef
88.
Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Publ Health. 2018;2018:60–6.CrossRef
89.
Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25:S27–33.CrossRef
90.
Ferry T, Kolenda C, Batailler C, Gustave C-A, Lustig S, Malatray M, et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front Med. 2020;7:570572.
91.
Racenis K, Rezevska D, Madelane M, Lavrinovics E, Djebara S, Petersons A, Kroica J. Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant Pseudomonas aeruginosa femur osteomyelitis—a case report. Front Med. 2022;9
92.
Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19:35–45.PubMedCrossRef
93.
Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley RT, editors. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open forum infectious diseases; 2020: Oxford University Press US.
94.
Duplessis C, Biswas B, Hanisch B, Perkins M, Henry M, Quinones J, et al. Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J Pediatric Infect Dis Soc. 2018;7:253–6.PubMedCrossRef
95.
Leitner L, Sybesma W, Chanishvili N, Goderdzishvili M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017;17:1–6.CrossRef
96.
Aslam S, Pretorius V, Lehman SM, Morales S, Schooley RT. Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Heart Lung Transpl. 2019;38:475–6.CrossRef
97.
Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjishvili N, Leshkasheli L, et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat Commun. 2022;13:302.PubMedPubMedCentralCrossRef
98.
Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 2022;13:4239.PubMedPubMedCentralCrossRef
99.
Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat Commun. 2022;13:5725.PubMedPubMedCentralCrossRef
100.
Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11:891.PubMedPubMedCentralCrossRef
101.
Lebeaux D, Merabishvili M, Caudron E, Lannoy D, Van Simaey L, Duyvejonck H, et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses. 2021;13:60.PubMedPubMedCentralCrossRef
102.
Van Nieuwenhuyse B, Galant C, Brichard B, Docquier P-L, Djebara S, Pirnay J-P, et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: Outcomes and phage-antibiotic interactions. Viruses. 2021;13:1898.PubMedPubMedCentralCrossRef
103.
Fedorov E, Samokhin A, Kozlova Y, Kretien S, Sheraliev T, Morozova V, et al. Short-term outcomes of phage-antibiotic combination treatment in adult patients with periprosthetic hip joint infection. Viruses. 2023;15:499.PubMedPubMedCentralCrossRef
104.
Doub JB, Chan B, Johnson AJ. Salphage: Salvage bacteriophage therapy for a chronic Enterococcus faecalis prosthetic joint infection. IDCases. 2023;33: e01854.PubMedPubMedCentralCrossRef
Metadata
Title
Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections
Authors
Majid Taati Moghadam
Ali Mojtahedi
Shakiba Salamy
Razieh Shahbazi
Naghmeh Satarzadeh
Majid Delavar
Mohammad Taghi Ashoobi
Publication date
02-02-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02178-0

Other articles of this Issue 2/2024

Infection 2/2024 Go to the issue

Brief Report

Population of invasive group A streptococci isolates from a German tertiary care center is dominated by the hypertoxigenic virulent M1UK genotype

Research

Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India

Research

Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study

Review

Helicobacter pylori and oral–gut microbiome: clinical implications

Brief Report

Characterization of blaOXA-48-carrying plasmids and small non-AMR-coding plasmids collected from Ukrainian patients

Review

Infiltration to infection: key virulence players of Helicobacter pylori pathogenicity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits